Journal article icon

Journal article

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.

Abstract:

Patients with high risk myelodysplasia (HR-MDS) and acute myeloid leukaemia (AML) with chromosomal changes involving deletion of the long arm of chromosome 5 (del5q), especially with complex karyotype, rarely have a durable response to combination chemotherapy. In the subgroup with monosomal karyotype there are no long term survivors (Fang et al., 2011) [1]. Recent experience indicates that the incidence of del5q in AML is ~20-30%, with only 20-25% of patients achieving complete remission (CR...

Expand abstract

Actions


Access Document


Publisher copy:
10.1016/j.lrr.2013.07.003

Authors


Culligan, D More by this author
Karamitros, D More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, Molecular Medicine, Biomedical Research
Johnson, P More by this author
Expand authors...
Journal:
Leukemia research reports
Volume:
2
Issue:
2
Pages:
70-74
Publication date:
2013
DOI:
EISSN:
2213-0489
ISSN:
2213-0489
URN:
uuid:30f76116-1384-4891-b724-44626f39ba1f
Source identifiers:
445639
Local pid:
pubs:445639

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP